Vioxx

Known as: Merck Frosst brand of rofecoxib, Merck brand of rofecoxib, Merck Sharp & Dhome brand of rofecoxib 
a kind of nonsteroidal anti-inflammatory drugs
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2007
Review
2007
http://bmj.com/cgi/content/full/334/7585/120 Updated information and services can be found at: These include: Data supplement… (More)
Is this relevant?
Review
2007
Review
2007
Clinical trial data have prompted questions about the degree to which patients and their physicians should consider an increased… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2005
2005
ble, and it would reduce rather than increase public expenditures. Well-targeted federally funded medication trials can more than… (More)
Is this relevant?
2005
2005
In many ways, 2004 will be a year that the drug discovery community would prefer to forget. During the past 12 months, questions… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
We have recently obtained information regarding inaccuracies in data in the report of the VIGOR (Vioxx Gastrointestinal Outcomes… (More)
  • table 1
  • table 2
Is this relevant?
Highly Cited
2004
Highly Cited
2004
On May 21, 1999, Merck was granted approval by the Food and Drug Administration (FDA) to market rofecoxib (Vioxx). On September… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
BACKGROUND The cyclo-oxygenase 2 inhibitor rofecoxib was recently withdrawn because of cardiovascular adverse effects. An… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Mutations in the human adenomatous polyposis (APC) gene are causative for familial adenomatous polyposis (FAP), a rare condition… (More)
  • table 1
  • table 3
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
1999
Highly Cited
1999
The discoveries that cyclooxygenase (COX)-2 is an inducible form of COX involved in inflammation and that COX-1 is the major… (More)
  • table 1
  • figure 2
  • figure 3
  • table 2
  • figure 4
Is this relevant?
1999
1999
The development of a COX-2 inhibitor rofecoxib (MK 966, Vioxx) is described. It is essentially equipotent to indomethacin both in… (More)
Is this relevant?